Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience

  • Héloïse Bourien
  • Xavier Palard
  • Yan Rolland
  • Fanny Le Du
  • Luc Beuzit
  • Thomas Uguen
  • Samuel Le Sourd
  • Marc Pracht
  • Vincent Manceau
  • Astrid Lièvre
  • Karim Boudjema
  • Etienne Garin
  • Julien EdelineEmail author
Original Article



Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality.


We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. We studied baseline characteristics as potential prognostic factors. We studied dose delivered to the tumor as predictive factors of outcomes in patients not receiving concomitant chemotherapy.


The Progression-Free Survival and Overall Survival (OS) were 7.6 months [95% Confidence Interval (CI): 4.6–10.6] and 16.4 months [95% CI: 7.8–25.0] in the whole cohort. The factors independently associated with OS in multivariable analysis were the primary localization of ICC (HR = 0.27, 95% CI: 0.11–0.68, p = 0.005) and a PS > 0 (HR = 2.21, 95% CI: 1.11–4.38, p = 0.024). During follow-up, 12 patients (19%) underwent surgery following downstaging, with a median OS of 51.9 months. In patients not treated with concomitant chemotherapy (n = 31), OS was significantly higher in patients with a dose delivered to the tumor 260Gy or higher than in patients with a dose delivered to the tumor lower than 260Gy (median 28.2 vs 11.4 months, log-rank p = 0.019).


Our results confirm that RE is a promising treatment modality in BTC. A high proportion of patients could be downstaged to surgery, with promising long-term survival. Dose delivered to the tumor correlated with clinical outcomes when chemotherapy was not used concomitantly.


Radioembolization Dosimetry Biliary tract cancer 90Y Intrahepatic cholangiocarcinoma 



This work was supported in part by a grant from the French National Agency for Research called “Investissements d’Avenir” n°ANR-11-LABX-0018-01.

Compliance with ethical standards

Conflict of interests

Etienne Garin, Yan Rolland and Julien Edeline are consultants for BTG, manufacturer of glass microspheres.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.


  1. 1.
    Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134–44.CrossRefGoogle Scholar
  2. 2.
    Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet Lond Engl. 2014;383:2168–79.CrossRefGoogle Scholar
  3. 3.
    Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRefGoogle Scholar
  4. 4.
    Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74.CrossRefGoogle Scholar
  5. 5.
    Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.CrossRefGoogle Scholar
  6. 6.
    Mosconi C, Gramenzi A, Ascanio S, Cappelli A, Renzulli M, Pettinato C, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115:297–302.CrossRefGoogle Scholar
  7. 7.
    Soydal C, Kucuk ON, Bilgic S, Ibis E. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors. Ann Nucl Med. 2016;30:29–34.CrossRefGoogle Scholar
  8. 8.
    Edeline J, Du FL, Rayar M, Rolland Y, Beuzit L, Boudjema K, et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med. 2015;40:851–5.CrossRefGoogle Scholar
  9. 9.
    Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42:59–64.CrossRefGoogle Scholar
  10. 10.
    Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol JVIR. 2014;25:256–65.CrossRefGoogle Scholar
  11. 11.
    Mouli S, Memon K, Baker T, Benson AB, Mulcahy MF, Gupta R, et al. Yttrium-90 Radioembolization for intrahepatic cholangiocarcinoma: safety, response. and Survival Analysis J Vasc Interv Radiol. 2013;24:1227–34.CrossRefGoogle Scholar
  12. 12.
    Hoffmann R-T, Paprottka PM, Schön A, Bamberg F, Haug A, Dürr E-M, et al. Transarterial hepatic Yttrium-90 Radioembolization in patients with Unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35:105–16.CrossRefGoogle Scholar
  13. 13.
    Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for Unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17:484–91.CrossRefGoogle Scholar
  14. 14.
    Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. J Cancer Res Clin Oncol. 2017;143:481–9.CrossRefGoogle Scholar
  15. 15.
    Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR, Tatsch K. Prognostic factors in overall survival of patients with Unresectable intrahepatic cholangiocarcinoma treated by means of Yttrium-90 Radioembolization: results in therapy-Naïve patients. Cardiovasc Intervent Radiol 2018.Google Scholar
  16. 16.
    Swinburne NC, Biederman DM, Besa C, Tabori NE, Fischman AM, Patel RS, et al. Radioembolization for Unresectable intrahepatic cholangiocarcinoma: review of safety, response evaluation criteria in solid tumors 1.1 imaging response and survival. Cancer Biother Radiopharm. 2017;32:161–8.CrossRefGoogle Scholar
  17. 17.
    Shaker TM, Chung C, Varma MK, Doherty MG, Wolf AM, Chung MH, et al. Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? Am J Surg. 2018;215:467–70.CrossRefGoogle Scholar
  18. 18.
    Cucchetti A, Cappelli A, Mosconi C, Zhong J-H, Cescon M, Pinna AD, et al. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study. Liver Int off J Int Assoc study. Liver. 2017;37:1056–64.CrossRefGoogle Scholar
  19. 19.
    Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.CrossRefGoogle Scholar
  20. 20.
    Garin E. Radioembolisation of hepatocellular carcinoma patients using 90Y-labelled microspheres: towards a diffusion of the technique? Eur J Nucl Med Mol Imaging. 2011;38:2114–6.CrossRefGoogle Scholar
  21. 21.
    Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging. 2018.Google Scholar
  22. 22.
    Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol JVIR. 2011;22:265–78.CrossRefGoogle Scholar
  23. 23.
    Garin E, Lenoir L, Rolland Y, Laffont S, Pracht M, Mesbah H, et al. Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres. Nucl Med Commun. 2011;32:1245–55.CrossRefGoogle Scholar
  24. 24.
    Zhu C-P, Shi J, Chen Y-X, Xie W-F, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol J Eur Soc Ther. Radiol Oncol. 2011;99:108–13.CrossRefGoogle Scholar
  25. 25.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009;45:228–47.Google Scholar
  26. 26.
    Beuzit L, Edeline J, Brun V, Ronot M, Guillygomarc’h A, Boudjema K, et al. Comparison of Choi criteria and response evaluation criteria in solid tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). Eur J Radiol. 2016;85:1445–52.CrossRefGoogle Scholar
  27. 27.
    Primrose J et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol ASCO Meet Abstr. 2017;35:Abstr 4006.Google Scholar
  28. 28.
    Edeline J et al. Adjuvant GEMOX for biliary tract cancer: updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. ESMO Conf. 2017;Abstr LBA 29.Google Scholar
  29. 29.
    Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, et al. Intra-arterial Yttrium-90 Radioembolization combined with systemic chemotherapy is a promising method for Downstaging Unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 2015.Google Scholar
  30. 30.
    Spolverato G, Yakoob MY, Kim Y, Alexandrescu S, Marques HP, Lamelas J, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015;22:4020–8.CrossRefGoogle Scholar
  31. 31.
    Farges O, Fuks D, Boleslawski E, Le Treut Y-P, Castaing D, Laurent A, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254:824–30.CrossRefGoogle Scholar
  32. 32.
    Wright GP, Perkins S, Jones H, Zureikat AH, Marsh JW, Holtzman MP, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies. Ann Surg Oncol. 2018;25:83–90.CrossRefGoogle Scholar
  33. 33.
    Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, et al. Gemcitabine and oxaliplatin, but not sorafenib or paclitaxel, have a synergistic effect with yttrium-90 in reducing hepatocellular carcinoma and cholangiocarcinoma cell line viability. J Vasc Interv Radiol JVIR. 2015;26:1874–1878.e2.CrossRefGoogle Scholar
  34. 34.
    Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559–75.CrossRefGoogle Scholar
  35. 35.
    Edeline J et al. Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study). ESMO Conf. 2017;Abstr 771P.Google Scholar
  36. 36.
    Kloeckner R, Ruckes C, Kronfeld K, Wörns MA, Weinmann A, Galle PR, et al. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials. 2014;15:311.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Héloïse Bourien
    • 1
  • Xavier Palard
    • 2
  • Yan Rolland
    • 3
  • Fanny Le Du
    • 1
  • Luc Beuzit
    • 4
  • Thomas Uguen
    • 5
  • Samuel Le Sourd
    • 1
  • Marc Pracht
    • 1
  • Vincent Manceau
    • 2
  • Astrid Lièvre
    • 6
  • Karim Boudjema
    • 7
  • Etienne Garin
    • 2
    • 8
  • Julien Edeline
    • 1
    • 8
    Email author
  1. 1.Medical OncologyCentre Eugène MarquisRennesFrance
  2. 2.Nuclear MedicineCentre Eugène MarquisRennesFrance
  3. 3.Interventional RadiologyCentre Eugène MarquisRennesFrance
  4. 4.RadiologyCHU PontchaillouRennesFrance
  5. 5.HepatologyCHU PontchaillouRennesFrance
  6. 6.GastroenterologyCHU PontchaillouRennesFrance
  7. 7.Hepatobiliary SurgeryCHU PontchaillouRennesFrance
  8. 8.Univ Rennes, INSERM, INRA, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer)RennesFrance

Personalised recommendations